Antares Pharma (ATRS) Misses Q2 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $4.62 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• Cooper Companies (COO) Reiterated at Buy by Stifel After Earnings Call